



Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wary et al.

§ ART UNIT:

FILED: March 29, 2004

§

§

§

§

§

§

§

§

SERIAL NO.: 10/812,238

FOR: Uses of Vascular Endothelial Growth  
Factor and Type 1 Collagen Inducible  
Protein (VCIP)

EXAMINER:

DOCKET:

D6563

MS DD

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

Dear Sir:

I hereby certify under 37 CFR 1.8 that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to: MS: DD, Commissioner of Patents, P.O. BOX 1450, Alexandria, VA 22313-1450, on the date indicated below.

- 1) Information Disclosure Statement; and
- 2) PTO Form 1449 (Five References cited)

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: Nov 15, 2006

ADLER & ASSOCIATES

8011 Candle Lane

Houston, Texas 77071

(713) 270-5391

Fax: (713) 270-5361

BADLER1@houston.rr.com

Benjamin Aaron Adler, Ph.D., J.D.

Registration No. 35,423

Counsel for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wary et al.

§ ART UNIT:

FILED: March 29, 2004

§

§

SERIAL NO.: 10/812,238

§

§

EXAMINER:

FOR: Uses of Vascular Endothelial

§

§

Growth Factor and Type 1

§

DOCKET

Collagen Inducible Protein (VCIP)

§

D6563

MS DD

Commissioner of Patents

P.O. BOX 1450

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Dear Sir:

Enclosed herewith for filing under 37 C.F.R. 1.97(c) in the above-referenced matter is form PTO-1449 together with copies of the references listed therein. Applicants state that each item of information contained in the information disclosure statement herein was cited in a communication from a foreign application not more than three months prior to the filing of the information disclosure statement. If any questions remain, the Examiner is respectfully requested to call the undersigned attorney at (713)-270-5391.

Respectfully submitted,

Date: Nov 15, 2006

ADLER & ASSOCIATES

8011 Candle Lane

Houston, Texas 77071

Phone: (713) 270-5391

Fax: (713) 270-5361

BADLER1@houston.rr.com

Benjamin Aaron Adler, Ph.D., J.D.

Registration No. 35,423

Counsel for Applicant



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Information Disclosure  
Statement

DOCKET NO.: D6563  
SERIAL NO.: 10/812,238  
APPLICANT: Wary, et al.  
FILING DATE: March 29, 2004  
GROUP:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
---------------------	--------------------	------	------	-------	----------	-------------

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Publication: Patent Cooperation Treaty (PCT)  
Translation: English  
Document Number: WO 98/46730 Date:  
Country: Great Britain

Class Or Subclass C12N 9/16  
Patent: Yes \_ No X  
Title: Human Phosphatidic Acid Phosphatase

Publication: Patent Cooperation Treaty (PCT)  
Translation: English  
Document Number: WO 95/28426 Date:  
Country: Great Britain

Class Or Subclass C07K 14/75  
Patent: Yes \_ No X  
Title: Peptides for Reducing or Inhibition Bone Resorption, Angiogenesis and Restenosis

OTHER DOCUMENTS (Including Author, Title, Place of Date, Publication)

\_\_\_ a. Wary, K. K. et al. *VCIP Induces Cell-Cell Interactions: Its Role in Angiogenesis*: Institute of Biosciences and Technology, November 2002, vol. 13, pp. 75a-76a

\_\_\_ b. Schabbert, S. et al. *Incorporation of (2S,3S) and (2S, 3R)  $\beta$ -Methyl Aspartic Acid into RGD-Containing Peptides*: Bioorganic & Medicinal Chemistry, October 2002, vol. 10, no. 10, pp. 3331-3337

\_\_\_ c. Humtsoe, J. O. et al.; *Regulation of Cell-Cell Interactions by Phosphatidic Acid Phosphatase 2b/VCIP*: The EMBO Journal, April 1, 2003 vol. 22, no. 7, pp. 1539-1554

Examiner Date Considered

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)